Diets promoting inflammation may slowly lead to depression, anxiety
Foods that promote inflammation appear to contribute to the development over time of depression and anxiety in people with…
Articles by Andrea Lobo, PhD
Healthcare utilization increases in the year before MS diagnosis: Study
People with multiple sclerosis (MS) utilize more healthcare resources a year before their MS diagnosis, suggesting this may be…
FDA grants fast track status to KYV-101 for progressive forms of MS
The U.S. Food and Drug Administration (FDA) has granted fast track status to KYV-101, Kyverna Therapeutics’ cell-based therapy candidate…
$40K grant will fund study of cycling and virtual reality for MS
A research team at the Kessler Foundation has received a $39,994 grant from the Consortium of Multiple Sclerosis Centers…
Acorda taking over global marketing of Fampyra, MS walking aid
Fampyra (fampridine), an approved oral treatment to improve the walking abilities of adults with multiple sclerosis (MS), soon will…
EU agency OKs study of therapy to improve mitochondrial function
Mitochon Pharmaceuticals is launching a pilot clinical trial to evaluate MP101, its treatment candidate for improving mitochondrial function, in…
Monte Rosa plans to begin Phase 1 trial of MRT-6160 in mid-2024
Monte Rosa Therapeutics is planning to initiate a Phase 1 clinical trial to test MRT-6160, its investigational therapy for…
SMS text messages may help MS patients self-manage fatigue: Study
Sending SMS text messages to people with multiple sclerosis (MS) — with tips for fatigue self-management and to regularly…
Remote coaching plus online tips ease stress of MS caregiving
Remote coaching sessions to support the mental and emotional health of informal multiple sclerosis (MS) caregivers, coupled with online…
In pilot trial, Ocrevus failed to reduce MS inflammation in meninges
Ocrevus (ocrelizumab) did not significantly reduce the number or volume of inflammatory lesions in the meninges in people with…
Ibudilast plus interferon-beta to get European patent for progressive MS
MediciNova announced the approval of a European patent covering the use of ibudilast (MN-166) in combination with…
Clinical trial of Scone device for overactive bladder still enrolling
Enrollment is nearly complete in a clinical trial of the Scone neuromodulation device in treating neurogenic, or overactive, bladder…
FDA puts partial hold on Phase 3 clinical trials of fenebrutinib in MS
The U.S. Food and Drug Administration (FDA) has placed a partial hold on Genentech’s ongoing Phase 3 clinical trials testing…
Blood levels of MIF protein may predict brain atrophy with PPMS
Higher blood levels of macrophage migration inhibitory factor (MIF), a molecule involved in inflammation, may predict a faster rate of…
EBV-001 vaccine prevents EBV infection in lab-grown human cells
EBV-001, a vaccine candidate being developed by EBViously to target the Epstein-Barr virus (EBV), triggered the production of potent…
4 new SPMS patients dosed with nasal foralumab outside of trials
Tiziana Life Sciences has dosed four new participants in an expanded access program investigating its foralumab nasal spray…
FDA clears BrainSpec’s tool to measure metabolites on brain scans
The U.S. Food and Drug Administration (FDA) has cleared BrainSpec Core, a platform that performs non-invasive measurements of brain chemistry,…
Providers weigh treatment logistics in selecting DMTs for MS patients
Certain clinical attributes of disease-modifying therapies (DMTs), such as safety and the medication’s impact on risk of relapse and disability…
Supplementation with coconut oil, green tea may help reduce triglycerides
Supplementation with coconut oil and the green tea component epigallocatechin gallate (EGCG) significantly reduces the levels of fatty molecules called…
Probiotic eased pain and fatigue in RRMS, trial data show
A commercial probiotic supplement containing the yeast Saccharomyces boulardii significantly eased pain and fatigue, and improved mental health and quality…
FDA names Elecsys NfL blood test for MS a breakthrough device
A test called Elecsys NfL — developed by Roche to measure blood levels of the nerve damage biomarker neurofilament…
First healthy volunteers dosed in Phase 1 trial of LPX-TI641
A Phase 1 clinical trial evaluating LPX-TI641, Lapix Therapeutics‘ experimental therapy for multiple sclerosis (MS) and other autoimmune…
ECTRIMS 2023: Most on Zeposia see slower disability progression
More than three-quarters of people with relapsing forms of multiple sclerosis (MS) who received Zeposia (ozanimod) in the…
Partnership seeks to drive diversity, inclusion in MS clinical trials
The Accelerated Cure Project for Multiple Sclerosis and the Arab Board for Clinical Research have partnered with the Association…
Heligenics IDs new interferon beta variants that might help in MS
Heligenics has discovered a number of variations in the interferon beta 1 (IFNB1) gene that may markedly improve the…
Tiziana seeks sites to conduct Phase 2a trial of nasal foralumab
Tiziana Life Sciences has started to recruit clinical sites for a Phase 2a clinical trial that will investigate its…
Tyruko, first Tysabri biosimilar, approved in Europe for RMMS
The European Commission has approved Tyruko (natalizumab), the first biosimilar of Tysabri, for the treatment of adults with…
Patient enrollment is complete in Phase 1 trial of ANK-700 for RRMS
Anokion has finished enrolling patients in the second part of its Phase 1 clinical trial investigating ANK-700 for…
Imcyse completes enrollment in Phase 1 trial testing IMCY-0141 for RRMS
Imcyse has completed patient enrollment and initial dosing in a Phase 1 clinical trial evaluating IMCY-0141, its next-generation immunotherapy,…
Benefits of long-term Tysabri seen in RRMS patients in Japan: Study
Tysabri (natalizumab) significantly reduced the development of brain lesions on MRI scans in Japanese people with relapsing-remitting multiple…